UK flag as shield

Ixekizumab for treating moderate to severe plaque psoriasis

Today NICE, England published final draft guidance recommending Ixekizumab for treating moderate to severe plaque psoriasis.  The draft guidance can be found here Ixekizumab is recommended as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or…

Read More
UK flag as shield

uk: Treat moderate to severely active ulcerative colitis

Treatment  recommendation: To treat moderate to severely active ulcerative colitis a final guidance was published recommending vedolizumab (Entyvio, Takeda) Vedolizumab provides a further treatment option when conventional therapy or TNF-alpha inhibitors either don’t work well, has stopped working or can’t be tolerated. Vedolizumab is recommended on basis it is provided to the NHS at a…

Read More